ABRAMS'mCLINICALmDRUGmTHERAPY:mRATIONALESmFORmNURSINGmPRACTICE
,ABRAMS'mCLINICALmDRUGmTHERAPY:mRATIONALESmFORmNURSINGmPRACTIC
E
,ABRAMS'mCLINICALmDRUGmTHERAPY:mRATIONALESmFORmNURSINGmPRACTIC
E
, ABRAMS'mCLINICALmDRUGmTHERAPY:mRATIONALESmFORmNURSINGmPRACTIC
E
Chapter 1, The Foundation of Pharmacology: Quality and Safety
m m m m m m m m
1. Amwomanmdiagnosedmwithmobsessive–
compulsivemdisordermhasmbeenmprescribedmoralmparoxetinemhydrochloride.mWhatm ism
themexpectedmeffectmformthismprescription?
A. Curativemeffectmonmsymptoms
B. Systemicmeffectmonmsymptoms
C. Localmeffectmonmsymptoms
D. Parenteralmeffectmonmsymptoms
ANS:m B
Rationale:mDrugsmthatmproducemsystemicmeffectsmaremtakenmintomthembody,mcirculatedmthrough
mthembloodstreammtomtheirmsitesmofmactionminmvariousmbodymtissues,mandmeventuallym eliminated
mfrommthembody.mCurativemagentsmarem givenmtomcuremamdiseasemprocess.m Inmthismcase,mparoxeti
nemhydrochloridemwillmcontrolmthemsymptomsmbutmnotmcuremthemdisorder.mDrugsmwithmlocalmeff
ects,msuchmasmsunscreenmandmlocalmanesthetics,mactmmainlymatmthemsitemofmapplication.mParoxeti
nemhydrochloridemismnotmadministeredmparenterally.mParenteralmagentsmaremadministeredmsubc
utaneously,m intramuscularly,mormintravenously.
PTS: 1 REF: p.m3,mIntroduction OBJ: 1
NAT:mClientmNeeds:mPhysiologicalmIntegrity:mPharmacologicalmandmParenteralmTherapi
esmTOP: Chapter:m1:mThemFoundationmofmPharmacology:m QualitymandmSafety
KEY:m IntegratedmProcess:mNursingmProcess
BLM:m CognitivemLevel:mUnderstand NOT:m MultiplemChoice
2. Amclientmhasmbeenmprescribedmanmantibiotic.mThismmedicationmismamnaturallymoccurring
substancemthatmhasmbeenmcheG
mRicAalDlyEm
SoBdOifOieSd.TW
.C
haOtmM
ismanothermnamem formthismtypemofmmedica
tion?
A. Syntheticmdrug
B. Semisyntheticmdrug
C. Biotechnologymdrug
D. Prototypemdrug
ANS:m B
Rationale:mSemisyntheticmdrugsm(e.g.,mmanymantibiotics)maremnaturallymoccurringmsubstancesm
thatmhavembeenmchemicallymmodified.mSyntheticmdrugsmaremmoremstandardizedminmtheirmchemic
almcharacteristics,mmoremconsistentminmtheirmeffects,mandmlessmlikelymtomproducemallergicmreacti
ons.mBiotechnologymdrugsminvolvemmanipulatingmDNAmandmRNAmandmrecombiningmgenesmin
tomhybridmmoleculesmthatmcanmbeminsertedmintomlivingmorganisms.mPrototypemdrugsmaremthemfir
stmdrugmofmamparticularmgroupmtom bemdeveloped.
PTS: 1 REF: p.m3,mDrugmSources OBJ: 1
NAT:mClientmNeeds:mPhysiologicalmIntegrity:mPharmacologicalmandmParenteralmTherapi
esmTOP: Chapter:m1:mThemFoundationmofmPharmacology:mQualitymandmSafety
KEY:m IntegratedmProcess:mNursingmProcess
BLM:m CognitivemLevel:mUnderstand NOT:m MultiplemChoice
3. Whichmclassificationmappliesmtommorphine?
A. Centralmnervousmsystemmdepressant
B. Centralmnervousmsystemmstimulant
,ABRAMS'mCLINICALmDRUGmTHERAPY:mRATIONALESmFORmNURSINGmPRACTIC
E
,ABRAMS'mCLINICALmDRUGmTHERAPY:mRATIONALESmFORmNURSINGmPRACTIC
E
, ABRAMS'mCLINICALmDRUGmTHERAPY:mRATIONALESmFORmNURSINGmPRACTIC
E
Chapter 1, The Foundation of Pharmacology: Quality and Safety
m m m m m m m m
1. Amwomanmdiagnosedmwithmobsessive–
compulsivemdisordermhasmbeenmprescribedmoralmparoxetinemhydrochloride.mWhatm ism
themexpectedmeffectmformthismprescription?
A. Curativemeffectmonmsymptoms
B. Systemicmeffectmonmsymptoms
C. Localmeffectmonmsymptoms
D. Parenteralmeffectmonmsymptoms
ANS:m B
Rationale:mDrugsmthatmproducemsystemicmeffectsmaremtakenmintomthembody,mcirculatedmthrough
mthembloodstreammtomtheirmsitesmofmactionminmvariousmbodymtissues,mandmeventuallym eliminated
mfrommthembody.mCurativemagentsmarem givenmtomcuremamdiseasemprocess.m Inmthismcase,mparoxeti
nemhydrochloridemwillmcontrolmthemsymptomsmbutmnotmcuremthemdisorder.mDrugsmwithmlocalmeff
ects,msuchmasmsunscreenmandmlocalmanesthetics,mactmmainlymatmthemsitemofmapplication.mParoxeti
nemhydrochloridemismnotmadministeredmparenterally.mParenteralmagentsmaremadministeredmsubc
utaneously,m intramuscularly,mormintravenously.
PTS: 1 REF: p.m3,mIntroduction OBJ: 1
NAT:mClientmNeeds:mPhysiologicalmIntegrity:mPharmacologicalmandmParenteralmTherapi
esmTOP: Chapter:m1:mThemFoundationmofmPharmacology:m QualitymandmSafety
KEY:m IntegratedmProcess:mNursingmProcess
BLM:m CognitivemLevel:mUnderstand NOT:m MultiplemChoice
2. Amclientmhasmbeenmprescribedmanmantibiotic.mThismmedicationmismamnaturallymoccurring
substancemthatmhasmbeenmcheG
mRicAalDlyEm
SoBdOifOieSd.TW
.C
haOtmM
ismanothermnamem formthismtypemofmmedica
tion?
A. Syntheticmdrug
B. Semisyntheticmdrug
C. Biotechnologymdrug
D. Prototypemdrug
ANS:m B
Rationale:mSemisyntheticmdrugsm(e.g.,mmanymantibiotics)maremnaturallymoccurringmsubstancesm
thatmhavembeenmchemicallymmodified.mSyntheticmdrugsmaremmoremstandardizedminmtheirmchemic
almcharacteristics,mmoremconsistentminmtheirmeffects,mandmlessmlikelymtomproducemallergicmreacti
ons.mBiotechnologymdrugsminvolvemmanipulatingmDNAmandmRNAmandmrecombiningmgenesmin
tomhybridmmoleculesmthatmcanmbeminsertedmintomlivingmorganisms.mPrototypemdrugsmaremthemfir
stmdrugmofmamparticularmgroupmtom bemdeveloped.
PTS: 1 REF: p.m3,mDrugmSources OBJ: 1
NAT:mClientmNeeds:mPhysiologicalmIntegrity:mPharmacologicalmandmParenteralmTherapi
esmTOP: Chapter:m1:mThemFoundationmofmPharmacology:mQualitymandmSafety
KEY:m IntegratedmProcess:mNursingmProcess
BLM:m CognitivemLevel:mUnderstand NOT:m MultiplemChoice
3. Whichmclassificationmappliesmtommorphine?
A. Centralmnervousmsystemmdepressant
B. Centralmnervousmsystemmstimulant
